Published in Diabetologia on November 04, 2010
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J (2011) 3.00
Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. Nat Med (2014) 2.15
Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications--a review. Nutr J (2014) 1.82
The kidney in type 2 diabetes therapy. Rev Diabet Stud (2011) 1.50
Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol (2014) 1.20
Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants. Diabetes Care (2012) 1.14
IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis. Arch Med Sci (2011) 1.12
Therapeutic effects of PPARα agonists on diabetic retinopathy in type 1 diabetes models. Diabetes (2012) 1.08
Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study. Diabetes Care (2011) 1.08
Coming full circle in diabetes mellitus: from complications to initiation. Nat Rev Endocrinol (2013) 1.01
Diabetic nephropathy: diagnosis and treatment. Nat Rev Endocrinol (2013) 0.98
Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism. Diabetes Care (2011) 0.96
Low HDL cholesterol and the risk of diabetic nephropathy and retinopathy: results of the ADVANCE study. Diabetes Care (2012) 0.95
Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes. Vasc Health Risk Manag (2013) 0.94
Selective peroxisome proliferator-activated receptor α modulators (SPPARMα): the next generation of peroxisome proliferator-activated receptor α-agonists. Cardiovasc Diabetol (2013) 0.93
Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease. World J Hepatol (2013) 0.92
Endothelial dysfunction in diabetes: pathogenesis, significance, and treatment. Rev Diabet Stud (2013) 0.91
Lipid-lowering agents in chronic kidney disease: do fibrates have a role? Nat Rev Cardiol (2013) 0.91
An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes. Diabetes (2013) 0.90
Using a multi-staged strategy based on machine learning and mathematical modeling to predict genotype-phenotype risk patterns in diabetic kidney disease: a prospective case-control cohort analysis. BMC Nephrol (2013) 0.86
Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis. J Am Soc Nephrol (2015) 0.84
Metabolic predictors of ischemic heart disease and cerebrovascular attack in elderly diabetic individuals: difference in risk by age. Cardiovasc Diabetol (2013) 0.84
The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system. Diab Vasc Dis Res (2014) 0.84
Refocusing Peroxisome Proliferator Activated Receptor-α: A New Insight for Therapeutic Roles in Diabetes. Diabetes Metab J (2013) 0.81
The evolving understanding of the contribution of lipid metabolism to diabetic kidney disease. Curr Diab Rep (2015) 0.81
Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study. BMC Nephrol (2014) 0.81
Do fibrates truly preserve kidney function? Nat Rev Endocrinol (2011) 0.81
The renoprotective actions of peroxisome proliferator-activated receptors agonists in diabetes. PPAR Res (2012) 0.81
Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience. Diabetologia (2012) 0.80
Effects of Omega-3 Fatty Acid Supplementation on Diabetic Nephropathy Progression in Patients with Diabetes and Hypertriglyceridemia. PLoS One (2016) 0.80
Plasma triglycerides predict incident albuminuria and progression of coronary artery calcification in adults with type 1 diabetes: the Coronary Artery Calcification in Type 1 Diabetes Study. J Clin Lipidol (2014) 0.80
Fibroblast growth factor 23 and incident CKD in type 2 diabetes. Clin J Am Soc Nephrol (2014) 0.79
The next generation of therapeutics for chronic kidney disease. Nat Rev Drug Discov (2016) 0.79
In vitro antimalarial activity and drug interactions of fenofibric acid. Antimicrob Agents Chemother (2012) 0.78
Primary prevention of diabetic retinopathy with fibrates: a retrospective, matched cohort study. BMJ Open (2013) 0.78
Use of fibrates in the metabolic syndrome: A review. World J Diabetes (2016) 0.78
Treatment and impact of dyslipidemia in diabetic nephropathy. Clin Exp Nephrol (2013) 0.78
Risk Factors for the Development and Progression of Diabetic Kidney Disease in Patients with Type 2 Diabetes Mellitus and Advanced Diabetic Retinopathy. Diabetes Metab J (2016) 0.78
Fenofibrate improves endothelial function and plasma myeloperoxidase in patients with type 2 diabetes mellitus: an open-label interventional study. Diabetol Metab Syndr (2014) 0.77
PPARα Activation Protects against Anti-Thy1 Nephritis by Suppressing Glomerular NF-κB Signaling. PPAR Res (2012) 0.77
Is there a role for hypolipidaemic drug therapy in the prevention or treatment of microvascular complications of diabetes? Open Cardiovasc Med J (2012) 0.77
Atherogenic dyslipidemia and combination pharmacotherapy in diabetes: recent clinical trials. Rev Diabet Stud (2013) 0.77
Tubular atrophy in the pathogenesis of chronic kidney disease progression. Pediatr Nephrol (2015) 0.76
Chapter 5: Triglyceride-lowering treatment in adults. Kidney Int Suppl (2011) (2013) 0.76
Diabetes: Should we use fibrates in patients with diabetes and mild CKD? Nat Rev Nephrol (2012) 0.75
The role of fibrates in chronic kidney disease and diabetes mellitus. Nat Rev Cardiol (2013) 0.75
Apolipoprotein-defined lipoproteins and apolipoproteins: associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort. J Diabetes Complications (2013) 0.75
Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia. Cardiovasc Diabetol (2017) 0.75
Diabetes and other endocrine-metabolic abnormalities in the long-term follow-up of pancreas transplantation. Clin Diabetes Endocrinol (2016) 0.75
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet (2005) 13.18
Publication bias: the case for an international registry of clinical trials. J Clin Oncol (1986) 12.14
Publication bias: evidence of delayed publication in a cohort study of clinical research projects. BMJ (1997) 9.69
Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet (2007) 6.82
Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood (1979) 6.01
Concordance for type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes mellitus in a population-based cohort of twins in Finland. Diabetologia (1992) 5.25
Association between dental health and acute myocardial infarction. BMJ (1989) 3.94
Quality-adjusted life years: origins, measurements, applications, objections. Aust J Public Health (1993) 3.59
Randomised comparison of procedures for obtaining informed consent in clinical trials of treatment for cancer. Br Med J (Clin Res Ed) (1986) 3.52
Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA (1997) 3.51
Does drinking carrot juice affect cancer of the prostate? Med J Aust (2001) 3.32
Antibiotics for sore throat. Cochrane Database Syst Rev (2006) 3.30
Characteristics of a neutralizing monoclonal antibody to the HIV envelope glycoprotein. AIDS Res Hum Retroviruses (1988) 2.99
Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treat Rev (2000) 2.78
Local hyperthermia in combination with definitive radiotherapy: increased tumor clearance, reduced recurrence rate in extended follow-up. Int J Radiat Oncol Biol Phys (1984) 2.72
Randomised controlled trial to change the hospital management of unstable angina. Med J Aust (2001) 2.64
Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. J Clin Oncol (1989) 2.57
Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population. Am J Epidemiol (1990) 2.56
Clinical characteristics and outcome of patients with early (<2 h), intermediate (2-4 h) and late (>4 h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction. Eur Heart J (2002) 2.49
Pravastatin therapy and the risk of stroke. N Engl J Med (2000) 2.46
Research output of Australian general practice: a comparison with medicine, surgery and public health. Med J Aust (2001) 2.44
The advanced glycation end product, Nepsilon-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem (1996) 2.42
Social alcohol consumption and low Lp(a) lipoprotein concentrations in middle aged Finnish men: population based study. BMJ (1998) 2.16
Antibiotics for sore throat. Cochrane Database Syst Rev (2004) 2.16
Is isopropyl alcohol swabbing before injection really necessary? Med J Aust (2001) 2.07
One-year results from the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) trial. GUSTO-I Investigators. Circulation (1996) 2.03
Apolipoprotein E phenotype determines the effect of alcohol on blood pressure in middle-aged men. Am J Hypertens (1998) 2.02
Is coenzyme Q10 helpful for patients with idiopathic cardiomyopathy? Med J Aust (2001) 2.01
Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Clin Radiol (2003) 2.00
QALYs for resource allocation: a reply to Burrows and Brown. Aust J Public Health (1993) 1.97
Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial. Circulation (1996) 1.87
Sweat testing for heroin, cocaine, and metabolites. J Anal Toxicol (1994) 1.86
Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr (2000) 1.77
Improving interpretation of clinical studies by use of confidence levels, clinical significance curves, and risk-benefit contours. Lancet (2001) 1.74
Insulin receptor expression in primary and cultured osteoclast-like cells. Bone (1998) 1.68
Diagnosis and management of ACTH-dependent Cushing's syndrome: comparison of the features in ectopic and pituitary ACTH production. Clin Endocrinol (Oxf) (1986) 1.62
Induction of morphological and functional differentiation of human promyelocytic leukemia cells (HL-60) by componuds which induce differentiation of murine leukemia cells. Int J Cancer (1980) 1.61
Plasma total bilirubin levels predict amputation events in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia (2013) 1.61
Valerian does not appear to reduce symptoms for patients with chronic insomnia in general practice using a series of randomised n-of-1 trials. Complement Ther Med (2003) 1.60
Antibiotics for sore throat. Cochrane Database Syst Rev (2000) 1.60
The effect of chronic sulfonylurea therapy on hepatic glucose production in non-insulin-dependent diabetes. Diabetes (1982) 1.59
Lymphocytic hypophysitis. The clinical spectrum of the disorder and evidence for an autoimmune pathogenesis. Clin Endocrinol (Oxf) (1990) 1.59
Confronting publication bias: a cohort design for meta-analysis. Stat Med (1987) 1.56
Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study. Lancet (2000) 1.56
Clinical and Pathological Report of Bilateral Glioma Retinae. Proc R Soc Med (1929) 1.55
Variation at the cholesteryl ester transfer protein gene in relation to plasma high density lipoproteins cholesterol levels and carotid intima-media thickness. Eur J Clin Invest (2001) 1.54
Is the development of adenoma and carcinoma in proximal colon related to apolipoprotein E phenotype? Gastroenterology (1996) 1.54
What cardiologists need to know about diabetes. Lancet (1997) 1.54
Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia (2010) 1.53
Sex-related differences in autonomic modulation of heart rate in middle-aged subjects. Circulation (1996) 1.50
Outcomes of a randomized controlled trial of a clinical pharmacy intervention in 52 nursing homes. Br J Clin Pharmacol (2001) 1.50
Meta-analysis of diagnostic tests with imperfect reference standards. J Clin Epidemiol (1999) 1.49
Accurate estimation of glomerular filtration rate in diabetic nephropathy from age, body weight, and serum creatinine. Diabetes Care (1992) 1.49
Quality adjusted survival analysis. Stat Med (1990) 1.48
Quantification of malondialdehyde and 4-hydroxynonenal adducts to lysine residues in native and oxidized human low-density lipoprotein. Biochem J (1997) 1.48
Apolipoprotein B gene polymorphisms and serum lipids: meta-analysis of the role of genetic variation in responsiveness to diet. Am J Clin Nutr (2000) 1.47
Stated and actual management of acute myocardial infarction among different specialties. Med J Aust (2000) 1.46
Association of metabolic syndrome with Alzheimer disease: a population-based study. Neurology (2006) 1.45
Apolipoprotein E phenotype and blood pressure. Lancet (1994) 1.45
Dynamic balanced randomization for clinical trials. Stat Med (1993) 1.44
Quality of life six months after myocardial infarction treated with thrombolytic therapy. AUS-TASK Group. Australian arm of International tPA/SK Mortality Trial. Med J Aust (1994) 1.43
A DNA fragment containing the groE genes can suppress mutations in the Escherichia coli dnaA gene. Mol Gen Genet (1986) 1.41
Feasibility of an evidence-based literature search service for general practitioners. Med J Aust (2001) 1.41
The postprandial state does not impair endothelial function in women with type 2 diabetes irrespective of glycaemic control. Diabetologia (2004) 1.40
Is laser treatment effective and safe for musculoskeletal pain? Med J Aust (2001) 1.39
Randomised controlled trials: elements of a good study. Med J Aust (2001) 1.38
Epstein-Barr virus shed in saliva is high in B-cell-tropic glycoprotein gp42. J Virol (2006) 1.38
Differential changes of autonomic nervous system function with age in man. Am J Med (1983) 1.36
Hypoglycemia masquerading as cerebrovascular disease (hypoglycemic hemiplegia). Ann Neurol (1985) 1.35
Patients' preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now? Ann Oncol (2005) 1.35
Serum cholestanol and plant sterol levels in relation to cholesterol metabolism in middle-aged men. Metabolism (1989) 1.33
Prevalence and prognosis of subjects with Brugada-type ECG pattern in a young and middle-aged Finnish population. Eur Heart J (2004) 1.32
Diabetes and arterial hypertension. Diabetologia (1983) 1.29
Association of apolipoprotein E phenotypes with late onset Alzheimer's disease: population based study. BMJ (1994) 1.29
Glycated haemoglobin and cardiovascular outcomes in people with Type 2 diabetes: a large prospective cohort study. Diabet Med (2008) 1.28
Prevalence of the metabolic syndrome in drug-treated hypertensive patients and control subjects. J Intern Med (1999) 1.27
Lipid-altering efficacy and safety of simvastatin 80 mg/day: long-term experience in a large group of patients with hypercholesterolemia. World Wide Expanded Dose Simvastatin Study Group. Clin Cardiol (2000) 1.27
Glycoconjugate structures of parasitic protozoa. Glycobiology (2001) 1.26
Glucose disposal is not proportional to plasma glucose level in man. Diabetes (1981) 1.26
Intestinal cholesterol absorption efficiency in man is related to apoprotein E phenotype. J Clin Invest (1987) 1.25
Apolipoprotein E and B polymorphisms--longevity factors assessed in nonagenarians. Atherosclerosis (1994) 1.25
A rapid increase in lipoprotein (a) levels after ethanol withdrawal in alcoholic men. Life Sci (1991) 1.24
Lipoxidation products as biomarkers of oxidative damage to proteins during lipid peroxidation reactions. Nephrol Dial Transplant (1996) 1.24
Cholesteryl ester transfer protein gene effect on CETP activity and plasma high-density lipoprotein in European populations. The EARS Group. Eur J Clin Invest (1999) 1.24
A comparison of LDL size determination using gradient gel electrophoresis and light-scattering methods. J Lipid Res (1998) 1.23
Increased serum pigment epithelium-derived factor is associated with microvascular complications, vascular stiffness and inflammation in Type 1 diabetes. Diabet Med (2007) 1.21
Standardization of insulin secretion from pancreatic islets: validation of a DNA assay. Horm Metab Res (1985) 1.18
All-cause mortality in the Canterbury (New Zealand) insulin-treated Diabetic Registry population. Diabetes Care (2001) 1.17
A chemical method for introducing haptens onto DNA probes. Anal Biochem (1988) 1.17